Long-term failure after transpupillary thermotherapy for small choroidal melanomas

Falha a longo prazo no tratamento do melanoma de coróide com termoterapia transpupilar

Gabriela Soncini Pasetto¹, Henrique Pedroso de Freitas¹, Carina Graziottin Colossi², Manuel Augusto Pereira Vilela³

ABSTRACT

Objective: To evaluate, retrospectively, in a long time interval, the results of transpupillary thermotherapy in selected cases of choroidal melanoma (CM). Methods: All patients with melanoma treated with transpupillary thermotherapy as sole therapy or supplement were identified. Cases with less than 60 months follow-up, incomplete records or abandonment of monitoring were excluded. Results: A total of 18 eyes, seven (38.9%) were included. Five (71.4%) patients were treated exclusively with transpupillary thermotherapy, in one (14.2%) eye criotherapy was used simultaneously, one (14.2%) was supplemented with brachytherapy – episcleral plate. Three (42.8%) had recurrence, two (28.5%) had metastases (one death), two eyes were enucleated. Complications were found in three eyes: two with macular folds, one with vitreous hemorrhage. In the enucleated eyes, extrascleral did not occur, however intrascleral tumoral cells were identified. Conclusion: Transpupillary thermotherapy shows a decline in its effectiveness and retains the risk of metastases in longer periods of follow-up, requiring a more exact definition of its role in choroidal melanoma.

Keywords: Melanoma/therapy; Choroidal; Hyperthermia, induced/methods

RESUMO

Objetivo: Avaliar, retrospectivamente, num longo intervalo de tempo, os resultados da termoterapia transpupilar em casos selecionados do melanoma de coróide. Métodos: Foram identificados todos os casos com melanoma de coróide tratados com termoterapia transpupilar, como terapia única ou suplementar. Foram excluídos os casos com seguimento inferior a 60 meses, prontuários incompletos ou com o abandono do acompanhamento. Resultados: De um total de 18 olhos, 7 (38.9%) foram incluídos no estudo. Cinco (71,4%) pacientes foram tratados exclusivamente com termoterapia transpupilar, em um (14,2%) olho a crioterapia foi simultânea, um (14,2%) suplementou braquiterapia – placa episcleral. Três (42,8%) sofreram recorrência, dois (28,5%) apresentaram metástases (um óbito), dois olhos foram enucleados. Complicações foram encontradas em três olhos: duas dobras maculares, uma hemorragia vítrea. Em dois olhos enucleados, extraescleral não ocorreu, porém células tumorais foram identificadas. Conclusão: Termoterapia transpupilar mostra um declínio em sua eficácia e conserva os riscos de metástases em períodos mais longos de acompanhamento, sendo necessária uma definição mais exata de seu papel nos melanomas de coróide.

Descritores: Melanoma/terapia; Coróide; Hipertermia induzida/métodos

¹Physicians at the Specialisation Course in Ophthalmology Professor Ivo Corrêa-Meyer. Porto Alegre/RS, Brazil.
²M.Sc., Preceptor at the Specialisation Course Professor Ivo Corrêa-Meyer. Porto Alegre/RS, Brazil.
³Ph.D., Professor of Ophthalmology, Federal University of Pelotas (UFPel), Pelotas/RS, Brazil.

Study conducted at the Federal University of Pelotas and the Specialisation Course in Ophthalmology Prof. Ivo Corrêa-Meyer, Porto Alegre/RS, Brazil.

The authors declare no conflict of interest.

Recebido para publicação em 24/4/2012 - Aceito para publicação em 24/10/2012
**INTRODUCTION**

Melanoma is the most frequent primary tumour of the eyeball. In its early stages it may be indistinguishable from a melanocytic nevus. It usually grows as a globular mass protruding toward the vitreous cavity. Ocular melanocytes are generally concentrated on the pigment epithelium, the uvea, and the conjunctival stroma. These cells have the same embryological origin of skin cells, i.e. the neural crest.

Specifically, choroidal melanoma (CM) occurs more frequently in the posterior pole and can present three different pigmentation patterns: amelanotic, densely pigmented, or mixed. In terms of appearance, the lesions may be nodular, multinodular, or diffuse.

For many years, enucleation was the treatment of choice for the condition. Currently, alternative therapeutic methods have been adopted that preserve the eyeball, and even its function, but without affecting the survival rate or the metastatic potential. These alternative therapeutic choices should take into account the patient's overall clinical condition, the affected eye's visual acuity and intraocular pressure, and the tumour's size, location, growth pattern, and activity. Within certain limits, expectant management is adequate; otherwise, therapeutic options include thermotherapy, brachytherapy, external radiotherapy, and surgical resection, among others.

Transpupillary thermotherapy (TTT) has emerged as a therapeutic option since 1998. In this technique, a laser beam — infrared radiation — is applied through the pupil to raise the temperature and destroy tumour tissue through cytotoxicity. The method can produce necrosis up to a maximum depth of 3.9 mm without affecting structures outside the treatment field. Its advantages include a limited field of action, the fact that it does not affect the survival rate or the metastatic potential. Among patients treated exclusively with TTT, 3 (60%) progressed with tumour control, 1 (20%) with tumour growth compared to the original lesion, and 1 (20%) with metastasis. Among those with tumour control, one (20%) developed vitreous haemorrhage (with spontaneous clearing within 3 weeks) and 1 (20%) developed macular folds. The patient who progressed with tumour regrowth (20%) underwent enucleation, and the patient with metastasis (20%) died after a follow-up of 65 months.

Disease control was not achieved in the patient who underwent TTT plus cryotherapy (14.2%), with tumour regrowth and macular folds. Its final result was enucleation. The patient treated with TTT plus episcleral plaque (14.2%) progressed with lung metastasis. This patient had been originally treated with TTT plus cryotherapy in the same surgical act, and patients who received TTT plus brachytherapy. Exclusion criteria were incomplete patient charts, a shorter follow-up period, and treatment dropouts.

The criteria and the technique adopted to indicate and perform TTT can be found in other sources; essentially, the method was limited to tumours up to 4 mm thick and 12 mm in diameter on ultrasound. Treatment was administered using a slit lamp (Opto, Brazil) under peribulbar block. Each patient had their demographic data collected and underwent an assessment of corrected visual acuity using Snellen's chart, assessment of extraocular movements, applanation tonometry, biomicroscopy, gonioscopy, and indirect binocular fundus examination. Retinography and fluorescein angiography were performed before the procedure and every 6 months afterwards. An oncological evaluation was performed every 6 months, with laboratory tests, ultrasound imaging, CT, and, in some cases, PET scan imaging. The study was approved by the Research Ethics Committee of the Federal University of Pelotas under number 00184/10.

**METHODS**

We studied cases of CM treated with TTT that had a minimum follow-up time of 60 months. Inclusion criteria were patients treated exclusively with TTT, patients who received “sandwich” therapy with TTT plus cryotherapy in the same surgical act, and patients who received TTT plus brachytherapy. Exclusion criteria were incomplete patient charts, a shorter follow-up period, and treatment dropouts.

Seven eyes of patients (four women) with MC were identified using the set criteria. Mean age was 58.8 years, ranging from 45 to 72 years. Of these, 5 (71.4%) were treated with TTT only, 1 (14.2%) with TTT plus cryotherapy, and 1 (14.2%) with TTT plus episcleral plaque. Mean tumour thickness was 3.7 mm, with a diameter of 5.35 mm. The mean follow-up time was 75.4 months (Table 1).

Among patients treated exclusively with TTT (5 eyes), 3 (60%) progressed with tumour control, 1 (20%) with tumour growth compared to the original lesion, and 1 (20%) with metastasis. Among those with tumour control, one (20%) developed vitreous haemorrhage (with spontaneous clearing within 3 weeks) and 1 (20%) developed macular folds. The patient who progressed with tumour regrowth (20%) underwent enucleation, and the patient with metastasis (20%) died after a follow-up of 65 months.

Disease control was not achieved in the patient who underwent TTT plus cryotherapy (14.2%), with tumour regrowth and macular folds. Its final result was enucleation.

The patient treated with TTT plus episcleral plaque (14.2%) progressed with lung metastasis. This patient had been originally treated with TTT plus cryotherapy in the same surgical act, and patients who received TTT plus brachytherapy. Exclusion criteria were incomplete patient charts, a shorter follow-up period, and treatment dropouts.

The criteria and the technique adopted to indicate and perform TTT can be found in other sources; essentially, the method was limited to tumours up to 4 mm thick and 12 mm in diameter on ultrasound. Treatment was administered using a slit lamp (Opto, Brazil) under peribulbar block. Each patient had their demographic data collected and underwent an assessment of corrected visual acuity using Snellen's chart, assessment of extraocular movements, applanation tonometry, biomicroscopy, gonioscopy, and indirect binocular fundus examination. Retinography and fluorescein angiography were performed before the procedure and every 6 months afterwards. An oncological evaluation was performed every 6 months, with laboratory tests, ultrasound imaging, CT, and, in some cases, PET scan imaging. The study was approved by the Research Ethics Committee of the Federal University of Pelotas under number 00184/10.

**RESULTS**

Seven eyes of patients (four women) with MC were identified using the set criteria. Mean age was 58.8 years, ranging from 45 to 72 years. Of these, 5 (71.4%) were treated with TTT only, 1 (14.2%) with TTT plus cryotherapy, and 1 (14.2%) with TTT plus episcleral plaque. Mean tumour thickness was 3.7 mm, with a diameter of 5.35 mm. The mean follow-up time was 75.4 months (Table 1).

Among patients treated exclusively with TTT (5 eyes), 3 (60%) progressed with tumour control, 1 (20%) with tumour growth compared to the original lesion, and 1 (20%) with metastasis. Among those with tumour control, one (20%) developed vitreous haemorrhage (with spontaneous clearing within 3 weeks) and 1 (20%) developed macular folds. The patient who progressed with tumour regrowth (20%) underwent enucleation, and the patient with metastasis (20%) died after a follow-up of 65 months.

Disease control was not achieved in the patient who underwent TTT plus cryotherapy (14.2%), with tumour regrowth and macular folds. Its final result was enucleation.

The patient treated with TTT plus episcleral plaque (14.2%) progressed with lung metastasis. This patient had been originally treated with TTT plus cryotherapy in the same surgical act, and patients who received TTT plus brachytherapy. Exclusion criteria were incomplete patient charts, a shorter follow-up period, and treatment dropouts.

The criteria and the technique adopted to indicate and perform TTT can be found in other sources; essentially, the method was limited to tumours up to 4 mm thick and 12 mm in diameter on ultrasound. Treatment was administered using a slit lamp (Opto, Brazil) under peribulbar block. Each patient had their demographic data collected and underwent an assessment of corrected visual acuity using Snellen's chart, assessment of extraocular movements, applanation tonometry, biomicroscopy, gonioscopy, and indirect binocular fundus examination. Retinography and fluorescein angiography were performed before the procedure and every 6 months afterwards. An oncological evaluation was performed every 6 months, with laboratory tests, ultrasound imaging, CT, and, in some cases, PET scan imaging. The study was approved by the Research Ethics Committee of the Federal University of Pelotas under number 00184/10.

**Table 1**

**Summary of treated cases.**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Tumour size(mm)</th>
<th>Colour</th>
<th>Site</th>
<th>Treatment</th>
<th>Course (months)</th>
<th>Complications</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, 49 years</td>
<td>2 x 20</td>
<td>Melanotic</td>
<td>Post-equator</td>
<td>TTT + episcleral plaque</td>
<td>96</td>
<td>Phthisis bulbi</td>
<td>Lung metastases recent surgery Controlled Death</td>
</tr>
<tr>
<td>Female, 64 years</td>
<td>3.1 x 2.9</td>
<td>Amelanotic</td>
<td>Nasal</td>
<td>TTT</td>
<td>64</td>
<td>Diffuse metastases</td>
<td>Controlled Death</td>
</tr>
<tr>
<td>Female, 45 years</td>
<td>3.2 x 2.0</td>
<td>Melanotic</td>
<td>Macular</td>
<td>TTT</td>
<td>65</td>
<td>Folds, regrowth</td>
<td>Enucleation</td>
</tr>
<tr>
<td>Female, 72 years</td>
<td>4.0 x 4.1</td>
<td>Melanotic</td>
<td>Equator</td>
<td>TTT + cryotherapy</td>
<td>72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, 65 years</td>
<td>3.8 x 3.2</td>
<td>Melanotic</td>
<td>Macular</td>
<td>TTT</td>
<td>65</td>
<td>Vitreous haemorrhage</td>
<td>Controlled Death</td>
</tr>
<tr>
<td>Male, 56 years</td>
<td>3.0 x 2.1</td>
<td>Melanotic</td>
<td>Post-equator</td>
<td>TTT</td>
<td>82</td>
<td>Regrowth</td>
<td>Enucleation</td>
</tr>
<tr>
<td>Male, 61 years</td>
<td>2.4 x 3.2</td>
<td>Amelanotic</td>
<td>Post-equator</td>
<td>TTT</td>
<td>84</td>
<td>Folds</td>
<td>Controlled</td>
</tr>
</tbody>
</table>

treated with brachytherapy only; however, tumour recurrence was observed at the edges, leading to TTT. Treatment was then supplemented with brachytherapy and episcleral plaque. The patient underwent lobe resection on both lungs and is under oncological follow-up. She has been followed-up for 96 months and has progressed to phthisis bulbi.

Histological examination of enucleated eyes found no extrascleral extension, but tumour cells were found in the scleral stroma.

Of the three eyes successfully treated (all exclusively with TTT), two suffered a significant loss of central vision: one due to macular folds and the other due to the submacular location of the mass (Figures 1-4).

DISCUSSION

Recent study results have led to a more cautious, less enthusiastic approach towards TTT in the treatment of CM, mainly because of the detection of viable tumour cells in the scleral parenchyma during follow-up. The depth to be reached can limit the method's efficiency, either in primary applications or reapplications\(^{(5-12)}\).

The choice to use TTT is based on the possibility of managing small lesions with a simple procedure that preserves the eyeball and, on certain cases, visual acuity. Early studies on TTT reported satisfactory and replicable results, but they had a short follow-up time\(^{(1-4)}\). More recently, different publications have supported a more cautious approach, and there is disagreement regarding the method's results and complications. The detection of treatment failures (local or distant metastases) depends on the study's follow-up period\(^{(6-13)}\).

Successful therapy with tumour control is achieved in 60-100% of cases, with patients undergoing 1-4 TTT sessions. However, the therapy's long-term results are controversial, with recent evidence suggesting that the method may be unable to destroy deeper tumour cells. In our study, the 2 cases that progressed to enucleation had tumour cells in the scleral lamellae, without extraocular extension — histopathological features similar to those described by Zaldivar and colleagues\(^{(5)}\).

The need for supplemental therapy is based mainly on the detection of tumour growth (in its thickness or margins) and subretinal fluid. Studies assessing the response to retreatment have also found divergent results, which may be due to different management strategies, but mainly due to differences in follow-up time.

Our study was limited due to its small, heterogeneous sample and its retrospective design. Still, we found a high frequency of tumour regrowth and metastasis.

Questions remain about the condition’s natural history and the influence of treatment on the prognosis of CM(12). Factors that may predict a poor prognosis include: tumour size(13-15), old age(16), tumour thickness(17), and involvement of the ciliary body(18). It is believed that a small, light CM takes 7 years to grow and another 4 years to develop metastases(12,18,19). The mortality rate of uveal melanoma is 31% in 5 years, 45% in 15 years, 49% in 25 years, and 52% in 35 years(12).

**CONCLUSION**

TTT in tumours up to 4 x 12 mm shows low effectiveness and does not eliminate the risk of metastasis in longer follow-up periods. Its role in the treatment of CM needs to be more clearly defined.

**REFERENCES**